The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 20…
CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian go…
CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows wit…
Agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid or…
The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 site…
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research…
Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million ov…
An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the prog…
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered in…
Popular search terms:
Americas
Asia Pacific
Europe
